• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

International Isotopes wins Imagyn deal

Article

Nuclear medicine start-up International Isotopes has won a major contract that will help the company in its quest to become a supplier of medical radioisotopes (SCAN 9/3/97). The company has signed a deal to provide its radioactive seeds to Imagyn

Nuclear medicine start-up International Isotopes has won a major contract that will help the company in its quest to become a supplier of medical radioisotopes (SCAN 9/3/97). The company has signed a deal to provide its radioactive seeds to Imagyn Medical Technologies, which will have exclusive worldwide rights to market the seeds for brachytherapy prostate cancer treatment, according to Newport Beach, CA-based Imagyn.

International Isotopes, of Denton, TX, will develop and manufacture the radioactive seeds for distribution through Imagyn's direct sales force. Imagyn will pay International Isotopes $1 million to develop the seeds and has agreed to purchase seeds for three years. Imagyn anticipates that it will file a 510(k) application for the company's initial brachytherapy product, iodine-125, with the Food and Drug Administration by March 31.

In other Imagyn news, the company has announced that it will close its Laguna Niguel, CA, plant and move its endoscope manufacturing facility to Costa Mesa, CA. As part of its consolidation, the firm is reducing its work force by about 120 people.

Related Videos
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Nina Kottler, MD, MS
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Related Content
© 2024 MJH Life Sciences

All rights reserved.